To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
44
CS-3150 2.5 to 5.0 mg , orally.
Japan Organaization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital
Yokohama, Kanagawa, Japan
Change from baseline in sitting blood pressure
Change from baseline in sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Time course of sitting blood pressure
Time course of sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Proportion of patients achieving sitting blood pressure goal
Time frame: Baseline to end of Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.